Lipiodol as a Fiducial Marker for Image-Guided Radiation Therapy for Bladder Cancer

Detalhes bibliográficos
Autor(a) principal: Freilich,Jessica M.
Data de Publicação: 2014
Outros Autores: Spiess,Philippe E., Biagioli,Matthew C., Fernandez,Daniel C., Shi,Ellen J., Hunt,Dylan C., Gupta,Shilpa, Wilder,Richard B.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Braz J Urol (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382014000200190
Resumo: Purpose To evaluate Lipiodol as a liquid, radio-opaque fiducial marker for image-guided radiation therapy (IGRT) for bladder cancer.Materials and Methods Between 2011 and 2012, 5 clinical T2a-T3b N0 M0 stage II-III bladder cancer patients were treated with maximal transurethral resection of a bladder tumor (TURBT) and image-guided radiation therapy (IGRT) to 64.8 Gy in 36 fractions ± concurrent weekly cisplatin-based or gemcitabine chemotherapy. Ten to 15mL Lipiodol, using 0.5mL per injection, was injected into bladder submucosa circumferentially around the entire periphery of the tumor bed immediately following maximal TURBT. The authors looked at inter-observer variability regarding the size and location of the tumor bed (CTVboost) on computed tomography scans with versus without Lipiodol.Results Median follow-up was 18 months. Lipiodol was visible on every orthogonal two-dimensional kV portal image throughout the entire, 7-week course of IGRT. There was a trend towards improved inter-observer agreement on the CTVboost with Lipiodol (p = 0.06). In 2 of 5 patients, the tumor bed based upon Lipiodol extended outside a planning target volume that would have been treated with a radiation boost based upon a cystoscopy report and an enhanced computed tomography (CT) scan for staging. There was no toxicity attributable to Lipiodol.Conclusions Lipiodol constitutes a safe and effective fiducial marker that an urologist can use to demarcate a tumor bed immediately following maximal TURBT. Lipiodol decreases inter-observer variability in the definition of the extent and location of a tumor bed on a treatment planning CT scan for a radiation boost.
id SBU-1_d27eaeb798aff8f3c275dee5bba7438e
oai_identifier_str oai:scielo:S1677-55382014000200190
network_acronym_str SBU-1
network_name_str International Braz J Urol (Online)
repository_id_str
spelling Lipiodol as a Fiducial Marker for Image-Guided Radiation Therapy for Bladder CancerEthiodized OilRadiotherapyUrinary BladderPurpose To evaluate Lipiodol as a liquid, radio-opaque fiducial marker for image-guided radiation therapy (IGRT) for bladder cancer.Materials and Methods Between 2011 and 2012, 5 clinical T2a-T3b N0 M0 stage II-III bladder cancer patients were treated with maximal transurethral resection of a bladder tumor (TURBT) and image-guided radiation therapy (IGRT) to 64.8 Gy in 36 fractions ± concurrent weekly cisplatin-based or gemcitabine chemotherapy. Ten to 15mL Lipiodol, using 0.5mL per injection, was injected into bladder submucosa circumferentially around the entire periphery of the tumor bed immediately following maximal TURBT. The authors looked at inter-observer variability regarding the size and location of the tumor bed (CTVboost) on computed tomography scans with versus without Lipiodol.Results Median follow-up was 18 months. Lipiodol was visible on every orthogonal two-dimensional kV portal image throughout the entire, 7-week course of IGRT. There was a trend towards improved inter-observer agreement on the CTVboost with Lipiodol (p = 0.06). In 2 of 5 patients, the tumor bed based upon Lipiodol extended outside a planning target volume that would have been treated with a radiation boost based upon a cystoscopy report and an enhanced computed tomography (CT) scan for staging. There was no toxicity attributable to Lipiodol.Conclusions Lipiodol constitutes a safe and effective fiducial marker that an urologist can use to demarcate a tumor bed immediately following maximal TURBT. Lipiodol decreases inter-observer variability in the definition of the extent and location of a tumor bed on a treatment planning CT scan for a radiation boost.Sociedade Brasileira de Urologia2014-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382014000200190International braz j urol v.40 n.2 2014reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/S1677-5538.IBJU.2014.02.08info:eu-repo/semantics/openAccessFreilich,Jessica M.Spiess,Philippe E.Biagioli,Matthew C.Fernandez,Daniel C.Shi,Ellen J.Hunt,Dylan C.Gupta,ShilpaWilder,Richard B.eng2014-06-10T00:00:00Zoai:scielo:S1677-55382014000200190Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2014-06-10T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false
dc.title.none.fl_str_mv Lipiodol as a Fiducial Marker for Image-Guided Radiation Therapy for Bladder Cancer
title Lipiodol as a Fiducial Marker for Image-Guided Radiation Therapy for Bladder Cancer
spellingShingle Lipiodol as a Fiducial Marker for Image-Guided Radiation Therapy for Bladder Cancer
Freilich,Jessica M.
Ethiodized Oil
Radiotherapy
Urinary Bladder
title_short Lipiodol as a Fiducial Marker for Image-Guided Radiation Therapy for Bladder Cancer
title_full Lipiodol as a Fiducial Marker for Image-Guided Radiation Therapy for Bladder Cancer
title_fullStr Lipiodol as a Fiducial Marker for Image-Guided Radiation Therapy for Bladder Cancer
title_full_unstemmed Lipiodol as a Fiducial Marker for Image-Guided Radiation Therapy for Bladder Cancer
title_sort Lipiodol as a Fiducial Marker for Image-Guided Radiation Therapy for Bladder Cancer
author Freilich,Jessica M.
author_facet Freilich,Jessica M.
Spiess,Philippe E.
Biagioli,Matthew C.
Fernandez,Daniel C.
Shi,Ellen J.
Hunt,Dylan C.
Gupta,Shilpa
Wilder,Richard B.
author_role author
author2 Spiess,Philippe E.
Biagioli,Matthew C.
Fernandez,Daniel C.
Shi,Ellen J.
Hunt,Dylan C.
Gupta,Shilpa
Wilder,Richard B.
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Freilich,Jessica M.
Spiess,Philippe E.
Biagioli,Matthew C.
Fernandez,Daniel C.
Shi,Ellen J.
Hunt,Dylan C.
Gupta,Shilpa
Wilder,Richard B.
dc.subject.por.fl_str_mv Ethiodized Oil
Radiotherapy
Urinary Bladder
topic Ethiodized Oil
Radiotherapy
Urinary Bladder
description Purpose To evaluate Lipiodol as a liquid, radio-opaque fiducial marker for image-guided radiation therapy (IGRT) for bladder cancer.Materials and Methods Between 2011 and 2012, 5 clinical T2a-T3b N0 M0 stage II-III bladder cancer patients were treated with maximal transurethral resection of a bladder tumor (TURBT) and image-guided radiation therapy (IGRT) to 64.8 Gy in 36 fractions ± concurrent weekly cisplatin-based or gemcitabine chemotherapy. Ten to 15mL Lipiodol, using 0.5mL per injection, was injected into bladder submucosa circumferentially around the entire periphery of the tumor bed immediately following maximal TURBT. The authors looked at inter-observer variability regarding the size and location of the tumor bed (CTVboost) on computed tomography scans with versus without Lipiodol.Results Median follow-up was 18 months. Lipiodol was visible on every orthogonal two-dimensional kV portal image throughout the entire, 7-week course of IGRT. There was a trend towards improved inter-observer agreement on the CTVboost with Lipiodol (p = 0.06). In 2 of 5 patients, the tumor bed based upon Lipiodol extended outside a planning target volume that would have been treated with a radiation boost based upon a cystoscopy report and an enhanced computed tomography (CT) scan for staging. There was no toxicity attributable to Lipiodol.Conclusions Lipiodol constitutes a safe and effective fiducial marker that an urologist can use to demarcate a tumor bed immediately following maximal TURBT. Lipiodol decreases inter-observer variability in the definition of the extent and location of a tumor bed on a treatment planning CT scan for a radiation boost.
publishDate 2014
dc.date.none.fl_str_mv 2014-04-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382014000200190
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382014000200190
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1677-5538.IBJU.2014.02.08
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv International braz j urol v.40 n.2 2014
reponame:International Braz J Urol (Online)
instname:Sociedade Brasileira de Urologia (SBU)
instacron:SBU
instname_str Sociedade Brasileira de Urologia (SBU)
instacron_str SBU
institution SBU
reponame_str International Braz J Urol (Online)
collection International Braz J Urol (Online)
repository.name.fl_str_mv International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)
repository.mail.fl_str_mv ||brazjurol@brazjurol.com.br
_version_ 1750318073627279360